Accelera – CROss Alliance® – The strong and long-lasting collaboration between CROSS and Accelera has been encouraged by the nature of the services we respectively provide, which can easily integrate each other.
The strong and long-lasting collaboration between CROSS and Accelera has been encouraged by the nature of the services we respectively provide, which can easily integrate each other.
Accelera is an Italian Contract Research Organisation (CRO) specialised in preclinical development and committed to discover, develop and deliver life-changing molecules.
Thanks to the complementarity of our clinical services we renewed our relationship during the years, this led us to the mutual attendance in the Swedish NLS Days for two consecutive and fruitful editions, and above all to the start of an official collaboration in 2021.
By this agreement Accelera and CROSS can provide their specific know how and experience in the always challenging transition from pre-clinical development to clinical trials in humans.
To learn more about our common project, read our informative material: Accelera-CROss Alliance® Translation Opportunity
To learn more about Accelera services visit: www.accelera.org
Centromedico – CROss Alliance® – For certain clinical studies CROss Alliance® needs to avail itself of external specialized professionals, a necessity which is satisfied by centromedico.
For certain clinical studies CROss Alliance® needs to avail itself of external specialized professionals in order to fulfil specific requirements of study protocols; for this reason, being able to rely on an external high qualified and trustable team is a necessity which is satisfied by centromedico.
Centromedico is a Swiss health service provider that offers patients a trustable and high quality service thanks to its experienced team, the technological modernity that distinguishes its performance and the required flexibility.
CROss Alliance® collaboration with centromedico started in the ophthalmology area but it is going to expand into other medical fields.
The success of the cooperation is guaranteed not only because centromedico accomplishes to meet CROSS’ diverse needs, but also because the common fundamental principle is a priority concept for both organisations: the importance of putting people first.
To learn more about centromedico services visit: https://centromedico.ch/it/
ERT – CROss Alliance® – eResearchTechnology Inc. (ERT) and CROss Alliance® announce to have in place a Joint Marketing Agreement, to mutually promote the activities of both organizations.
eResearchTechnology Inc. (ERT) and CROss Alliance® announce to have in place a Joint Marketing Agreement, to mutually promote the activities of both organizations.
After a successful collaboration of several years in QTc prolongation studies, CROss Alliance® and ERT have developed a mutually successful and meaningful working relationship. CROss Alliance® has selected ERT as a preferred cardiac safety provider for all trials to be performed at the CROSS Research Phase I unit in Switzerland and in support of all CROss trials around Europe. ERT has included CROSS Research Phase I unit among their recommended Clinical Phase I units in Europe.
A broad range of joint marketing activities will be performed through the year, including joint client visits, preparation of promotion documentation and joint attendance at Congresses. Based on the expertise and reliability of CROss Alliance® and ERT, this agreement is certain to provide continued high quality services to our clients.
To learn more about ERT services visit: www.ert.com
Unilabs – CROss Alliance® – For more than 10 years CROss Alliance® has been availing itself of Unilabs Ticino services for laboratory safety testing, creating a long-lasting and fruitful collaboration in which Unilabs provides to CROSS group a tailored and highly professional service.
Clinical trials can require more than one samples pick-up a day, Unilabs satisfies this type of request for CROSS Research Phase I Unit located in Arzo (TI) and through an efficient IT system allows CROSS physicians a rapid consultation of the analysis results within 24 hours from the pick-up.
This additional service represents a great advantage not only concerning time optimization, but also to guarantee the safety of the subjects participating a clinical study in our phase I unit.
Unilabs SA works in accordance with ISO/IEC 17025 and ISO 15189 Laboratory Practice, and it has been routinely audited by CROss Alliance® QA Unit, always with exemplary results.
To learn more about Unilabs services visit: https://unilabs.ch/it